Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.

Yoshimasa AsoKanako KatoShintaro SakuraiHaruka KishiMasanori ShimizuTeruo JojimaToshie IijimaYuko MaejimaKenju ShimomuraIsao Usui

Published in: International journal of clinical practice (2019)

Improvement of liver dysfunction after treatment with dapagliflozin was associated with a decrease in serum sDPP-4, suggesting that reduction of serum sDPP-4 by SGLT2 inhibitors may be a therapeutic strategy for NAFLD/NASH in patients with type 2 diabetes that is independent of glucose lowering or weight loss.

Keyphrases

weight loss
bariatric surgery
oxidative stress
roux en y gastric bypass
blood glucose
gastric bypass
type diabetes
body mass index
glycemic control
weight gain